Dalfampridine is a potassium channel blocker indicated to improve walking ability in patients with multiple sclerosis by inhibiting voltage-gated potassium channels in the spinal cord. Laboratories involved… Read more
![Chemical structure of 1,2,3,5,6,7-Hexahydrodicyclopenta[b,e]pyridin-8-amine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F62732-43-8-123567-Hexahydrodicyclopentabepyridin-8-amine.png&w=3840&q=75)





![Chemical structure of [2,2'-Bipyridine]-5,5'-diamine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F52382-48-6-22-Bipyridine-55-diamine.png&w=3840&q=75)
















Dalfampridine is a potassium channel blocker indicated to improve walking ability in patients with multiple sclerosis by inhibiting voltage-gated potassium channels in the spinal cord. Laboratories involved in pharmaceutical quality control and regulatory compliance require precise Dalfampridine reference standards to ensure the accuracy and reliability of their analytical methods. This category includes a comprehensive selection of pharmacopeial and non-pharmacopeial impurities, which are essential for robust impurity profiling and stability testing. These compounds represent potential degradation products arising from synthesis or environmental stress, such as oxidation and hydrolysis, and are critical for evaluating the safety and efficacy of the drug. Additionally, stable isotope labelled compounds are available to serve as internal standards in mass spectrometry-based analytical testing, facilitating precise quantification and verification in complex matrices.